Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment.

Sewell J, Daskalopoulou M, Nakagawa F, Lampe FC, Edwards S, Perry N, Wilkins E, O'Connell R, Jones M, Collins S, Speakman A, Phillips AN, Rodger AJ; Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group.

HIV Med. 2017 Aug;18(7):463-473. doi: 10.1111/hiv.12477. Epub 2016 Dec 22.

2.

Age, time living with diagnosed HIV infection, and self-rated health.

McGowan JA, Sherr L, Rodger AJ, Fisher M, Miners A, Anderson J, Johnson MA, Elford J, Collins S, Hart G, Phillips AN, Speakman A, Lampe FC; Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group.

HIV Med. 2017 Feb;18(2):89-103. doi: 10.1111/hiv.12398. Epub 2016 Jul 7.

3.

Short Communication: Diagnosis of Pneumocystis jirovecii Pneumonia by Detection of DNA in Blood and Oropharyngeal Wash, Compared with Sputum.

van Halsema C, Johnson L, Baxter J, Douthwaite S, Clowes Y, Guiver M, Ustianowski A.

AIDS Res Hum Retroviruses. 2016 May;32(5):463-6. doi: 10.1089/AID.2015.0213. Epub 2016 Feb 11.

PMID:
26739439
4.

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.

Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Scott K, Dunn DT; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team.

Lancet HIV. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3018(15)00176-9. Epub 2015 Sep 14.

5.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

6.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.

HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.

7.

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.

Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW; Nevirapine Toxicogenomics Study Team.

AIDS. 2011 Jun 19;25(10):1271-80. doi: 10.1097/QAD.0b013e32834779df.

Supplemental Content

Loading ...
Support Center